MORRISTOWN, N.J. Watson Pharmaceuticals has appointed R. Todd Joyce as SVP and CFO, the generic drug maker announced Friday.
Joyce succeeds Mark Durand, who left the CFO post for unspecified personal reasons, though the company announced in July that Durand had taken a leave of absence for health reasons, naming Joyce as acting principal financial officer.
“I, the board of directors and the senior management team wish to thank Mark for his service to the company,” Watson CEO Paul Bisaro said in a statement. “We appreciate this was a difficult decision for him and wish him well in the future. We are fortunate that Todd, who has served in a variety of senior financial positions within the company over the past 12 years, has agreed to become our new CFO.”